Abstract: The present application provides anti-CD137 constructs that bind to CD137 (e.g., anti-CD137 monoclonal antibodies and multispecific antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD137 constructs, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD137 constructs, pharmaceutical compositions containing the anti-CD137 constructs, and methods of using the anti-CD137 constructs or compositions.

Abstract: A method for preparing voriconazole L-camphorsulphonate and voriconazole. The method for preparing voriconazole L-camphorsulphonate comprises: method 1: dissolving (2R,3S)/(2S,3R) isomer mixture and L-camphor sulphonic acid in water and acetone, and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate; method 2: (a) dissolving a mixture of isomer mixture and L-camphor sulphonic acid in a first solvent and then performing crystallisation filtration; or (a?) dissolving L-camphorsulphonate of the isomer mixture in a first solvent and then performing crystallisation filtration; (b) concentrating the filtrate obtained in step (a) or (a?) into a solid; and (c) dissolving the solid obtained in step (b) in a second solvent and performing crystallisation filtration to obtain voriconazole L-camphorsulphonate. Adjusting the resolution solvent effectively reduces production costs and facilitates recycling of the resolution solvent.

Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3. The antibody derivative is a multispecific antibody that binds to GPC3 and an additional antigen, e.g., 4-1BB.

Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3.

Abstract: The present invention relates to anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT.

Abstract: A test piece holder for coalbed fracturing comprises a pressure chamber, first sliding rods, second sliding rods, third sliding rods, fourth sliding rods, fifth sliding rods, oil cylinders and a sealing ring, upper and lower ends of a test piece are both provided with an electrode needle and a gas-guide and liquid-guide conducting bolt, the gas-guide and liquid-guide conducting bolt has a hollow rod structure, an inside end of the gas-guide and liquid-guide conducting bolt located above is communicated with a water-gas channel and an outside end of the gas-guide and liquid-guide conducting bolt located above is a water-gas outlet, an inside end of the gas-guide and liquid-guide conducting bolt located below is communicated with the water-gas channel and an outside end of the gas-guide and liquid-guide conducting bolt located below is respectively provided with a gas inlet and a water inlet.

Abstract: Disclosed is a real-time nondestructive observation and two-phase seepage test system for a fracture of an in-situ fractured gas-bearing reservoir, which comprises a stress loading system, a high-voltage electric pulse fracturing operation system, a water-gas two-phase seepage system and an in-situ CT scanning system; the stress loading system comprises a pressure chamber, an axial pressure loading module and a confining pressure loading module; the high-voltage electric pulse fracturing operation system comprises a high-voltage electric pulse generation module, a high-voltage electric pulse signal monitoring module and a protection module; the water-gas two-phase seepage system comprises a water-gas pressure loading module and a flow data acquisition module; and the in-situ CT scanning system comprises a radiation source, a flat panel detector and a CT scanning detection mechanism.

Abstract: Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. The anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. The one or more additional antigen comprises Programmed death protein 1 (PD1).

Abstract: The present invention provides anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigen, and methods of using the same. In certain embodiments, the one or more additional antigen comprises epidermal growth factor receptor (EGFR).

Abstract: Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. In certain embodiments, the one or more additional antigen comprises Programmed cell death ligand 1 (PDL1).

Abstract: Provided are anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigens, and methods of using the same. In certain embodiments, the one or more additional antigens comprise human epidermal growth factor receptor 2 (HER2).

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: A method of using a device for conducting a vascular hemodynamic bionic cell experiment is provided, the method comprises: firstly, experiment preparation; and secondly, experiment operation, namely, switching on a peristaltic pump, pumping a circulation liquid from a collection bottle into an independently corresponding shunting chamber of a corresponding shunting bottle through a collection bottle sampling tube of an independent chamber of a collection bottle, after shunting by the shunting chamber of the shunting bottle, the circulation liquid flowing out of a branch shunting tube flows to a corresponding flow chamber on the 1-3 flow chamber platforms placed side by side, and then converging the circulation liquid to a corresponding independent chamber of the collection bottle through respective sampling tubes of the flow chamber platforms.

Abstract: A method of using a device for conducting a vascular hemodynamic bionic cell experiment is provided, the method comprises: firstly, experiment preparation; and secondly, experiment operation, namely, switching on a peristaltic pump, pumping a circulation liquid from a collection bottle into an independently corresponding shunting chamber of a corresponding shunting bottle through a collection bottle sampling tube of an independent chamber of a collection bottle, after shunting by the shunting chamber of the shunting bottle, the circulation liquid flowing out of a branch shunting tube flows to a corresponding flow chamber on the 1-3 flow chamber platforms placed side by side, and then converging the circulation liquid to a corresponding independent chamber of the collection bottle through respective sampling tubes of the flow chamber platforms.

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.

Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.

Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.